shannah
Senior Member
- Messages
- 1,429
Anybody know anything about this drug?
Possible New Chronic Fatigue Syndrome Drug Investigated
Wednesday August 25, 2010
http://chronicfatigue.about.com/b/2010/08/25/droxidopa-chronic-fatigue-syndrome.htm
A drug called droxidopa is now moving into phase II clinical trials as a treatment for chronic fatigue syndrome.
Droxidopa is a synthetic version of a substance your body uses to make the neurotransmitter/hormone norepinephrine. Norepinephrine performs several important functions, and you body also uses it to produce dopamine, another important neurotransmitter. Studies have shown that this drug can improve fatigue, weakness, concentration, and orthostatic hypotension (blood pressure drop upon standing, which causes dizziness) in several conditions, including Parkinson's disease. These symptoms are also common in chronic fatigue syndrome, and studies show that some people with this condition may have low levels of norepinephrine and dopamine.
The study will take place at the Hunter-Hopkins Center in Charlotte, North Carolina, under the supervision of Dr. Charles Lapp. Lapp has been involved in both the American Association for CFS and the American Fibromyalgia Syndrome Association.
Droxidopa also is being studied as a possible fibromyalgia treatment. It is not yet approved for any use in the U.S. However, its manufacturer, Chelsea Therapeutics, is working toward approval for neurogenic orthostatic hypotension.
Possible New Chronic Fatigue Syndrome Drug Investigated
Wednesday August 25, 2010
http://chronicfatigue.about.com/b/2010/08/25/droxidopa-chronic-fatigue-syndrome.htm
A drug called droxidopa is now moving into phase II clinical trials as a treatment for chronic fatigue syndrome.
Droxidopa is a synthetic version of a substance your body uses to make the neurotransmitter/hormone norepinephrine. Norepinephrine performs several important functions, and you body also uses it to produce dopamine, another important neurotransmitter. Studies have shown that this drug can improve fatigue, weakness, concentration, and orthostatic hypotension (blood pressure drop upon standing, which causes dizziness) in several conditions, including Parkinson's disease. These symptoms are also common in chronic fatigue syndrome, and studies show that some people with this condition may have low levels of norepinephrine and dopamine.
The study will take place at the Hunter-Hopkins Center in Charlotte, North Carolina, under the supervision of Dr. Charles Lapp. Lapp has been involved in both the American Association for CFS and the American Fibromyalgia Syndrome Association.
Droxidopa also is being studied as a possible fibromyalgia treatment. It is not yet approved for any use in the U.S. However, its manufacturer, Chelsea Therapeutics, is working toward approval for neurogenic orthostatic hypotension.